Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study

The Lancet Public Health

Volumn 2, Issue 7, 2017, Pages e331-e340

  Lew, Jie Bin ^a,b   St John, D James B ^c,d   Xu, Xiang Ming ^b   Greuter, Marjolein J E ^e   Caruana, Michael ^a,b   Cenin, Dayna R ^f,g   He, Emily ^a,b   Saville, Marion ^d,h   Grogan, Paul ⁱ   Coupé, Veerle M H ^e   Canfell, Karen ^a,b,j  

^a CANCER RESEARCH DIVISION   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c CANCER EPIDEMIOLOGY CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f CURTIN UNIVERSITY   (Australia)

^g ERASMUS MEDICAL CENTER   (Netherlands)

^h VICTORIAN CYTOLOGY SERVICE   (Australia)

ⁱ Cancer Council Australia   (Australia)

^j UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUSTRALIA; CANCER CONTROL; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER THERAPY; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; HUMAN; MASS SCREENING; NATIONAL BOWEL CANCER SCREENING PROGRAM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIMULATION; SYSTEMATIC REVIEW (TOPIC); AGED; CHEMISTRY; COLORECTAL TUMOR; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMICS; EVALUATION STUDY; FECES; MIDDLE AGED; OCCULT BLOOD; PROGRAM EVALUATION; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL;

AGED; AUSTRALIA; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FECES; HUMANS; MIDDLE AGED; MODELS, THEORETICAL; OCCULT BLOOD; PROGRAM EVALUATION; RISK ASSESSMENT;

EID: 85021060639     PISSN: None     EISSN: 24682667     Source Type: Journal    
DOI: 10.1016/S2468-2667(17)30105-6     Document Type: Article

References (37)

1. Australian Institute of Health and Welfare (AIHW). Australian Cancer Incidence and Mortality (ACIM) books: Colorectal cancer (also called bowel cancer). http://www.aihw.gov.au/acim-books, 2017 (accessed March 6, 2017).
2. Ananda, S, Kosmider, S, Tran, B, et al. The rapidly escalating cost of treating colorectal cancer in Australia. Asia Pac J Clin Oncol 12 (2016), 33–40.
3. Australian Bureau of Statistics. 3101.0 Australian Demographic Statistics. http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3101.0Main+Features1Jun%202016?OpenDocument, June, 2016 (accessed Dec 29, 2016).
4. Hewitson, P, Glasziou, P, Watson, E, Towler, B, Irwig, L, Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 103 (2008), 1541–1549.
5. Australian Institute of Health and Welfare (AIHW). National Bowel Cancer Screening Program: monitoring report 2016. Cancer series No. 98. Cat. no. CAN 97, 2016, AIHW, Canberra.
6. Bishop, J, Glass, P, Tracey, E, et al. Health Economics Review of Bowel Cancer Screening in Australia, 2008, Cancer Institute NSW, Sydney.
7. Pignone, MP, Flitcroft, KL, Howard, K, Trevena, LJ, Salkeld, GP, St John, DJ, Costs and cost-effectiveness of full implementation of a biennial faecal occult blood test screening program for bowel cancer in Australia. Med J Aust 194 (2011), 180–185.
8. Cenin, DR, St John, DJ, Ledger, MJ, Slevin, T, Lansdorp-Vogelaar, I, Optimising the expansion of the National Bowel Cancer Screening Program. Med J Aust 201 (2014), 456–461.
9. Greuter, MJ, Xu, XM, Lew, JB, et al. Modeling the Adenoma and Serrated pathway to Colorectal CAncer (ASCCA). Risk Anal 34 (2014), 889–910.
10. Stoop, EM, de Haan, MC, de Wijkerslooth, TR, et al. Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial. Lancet Oncol 13 (2012), 55–64.
11. Australian Institute of Health and Welfare (AIHW). Australian Cancer Incidence and Mortality (ACIM) books: Colorectal cancer (also called bowel cancer). http://www.aihw.gov.au/acim-books, 2016 (accessed Dec 28, 2016).
12. Australian Institute of Health and Welfare (AIHW). National Bowel Cancer Screening Program: monitoring report 2013–14. Cancer series No. 94. Cat. no. CAN 94, 2015, AIHW, Canberra.
13. Australian Institute of Health and Welfare (AIHW). National Bowel Cancer Screening Program monitoring report: phase 2, July 2008–June 2011. Cancer series no. 65. Cat no. CAN 61, 2012, AIHW, Canberra.
14. Australian Institute of Health and Welfare (AIHW). National Bowel Cancer Screening Program monitoring report: July 2011–June 2012. Cancer series no. 75. Cat. no. CAN 71, 2013, AIHW, Canberra.
15. Australian Institute of Health and Welfare (AIHW). National Bowel Cancer Screening Program monitoring report: 2012–2013. Cancer series No. 84. Cat. no. CAN 81, 2014, AIHW, Canberra.
16. Australian Institute of Health and Welfare & Australian Government Department of Health and Ageing. National Bowel Cancer Screening Program: monitoring report 2008. Cancer series no. 44. Cat. no. CAN 40, 2008, AIHW, Canberra.
17. van Rijn, JC, Reitsma, JB, Stoker, J, Bossuyt, PM, van Deventer, SJ, Dekker, E, Polyp miss rate determined by tandem colonoscopy: a systematic review. Am J Gastroenterol 101 (2006), 343–350.
18. Pickhardt, PJ, Hassan, C, Halligan, S, Marmo, R, Colorectal cancer: CT colonography and colonoscopy for detection—systematic review and meta-analysis. Radiology 259 (2011), 393–405.
19. Ananda, SS, McLaughlin, SJ, Chen, F, et al. Initial impact of Australia's National Bowel Cancer Screening Program. Med J Aust 191 (2009), 378–381.
20. Parente, F, Vailati, C, Boemo, C, et al. Improved 5-year survival of patients with immunochemical faecal blood test-screen-detected colorectal cancer versus non-screening cancers in northern Italy. Dig Liver Dis 47 (2015), 68–72.
21. Gill, MD, Bramble, MG, Hull, MA, et al. Screen-detected colorectal cancers are associated with an improved outcome compared with stage-matched interval cancers. Br J Cancer 111 (2014), 2076–2081.
22. Pande, R, Froggatt, P, Baragwanath, P, Harmston, C, Survival outcome of patients with screening versus symptomatically detected colorectal cancers. Colorectal Dis 15 (2013), 74–79.
23. Australian Bureau of Statistics. 3101.0—Australian Demographic Statistics, Sep 2014. http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/3101.0Main+Features1Sep%202014, 2015 (accessed June 13, 2017).
24. Australian Bureau of Statistics. 3222.0—Population Projections, Australia, 2012 (base) to 2101. http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/3222.0main+features32012%20(base)%20to%202101, 2013 (accessed June 13, 2017).
25. Knudsen, AB, Zauber, AG, Rutter, CM, et al. Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force. JAMA 315 (2016), 2595–2609.
26. Australian Cancer Network Colorectal Cancer Guidelines Revision Committee. Clinical Practical Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer, 2005, The Cancer Council Australia and Australian Cancer Network, Sydney.
27. Barclay, K, Cancer Council Australia Surveillance Colonoscopy Guidelines Working Party. Algorithm for Colonoscopic Surveillance Intervals—Adenomas. http://www.gastroservices.com.au/pdf/algorithm-for-colonoscopic-surveillance-intervals-adenomas.pdf, 2013 (accessed Dec 28, 2016).
28. Australian Government Department of Health. The Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines. Available from: https://pbac.pbs.gov.au/section-d/section-d-cea/d4-variables-in-the-economic-evaluation.html, 2016 (accessed Dec 22, 2016).
29. Lew, JB, Simms, K, Smith, M, et al. National Cervical Screening Program Renewal: Effectiveness modelling and economic evaluation in the Australian setting. Report to the Medical Services Advisory Committee, 2014, Department of Health and Ageing, Australia.
30. Sharp, L, Tilson, L, Whyte, S, et al. Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy. Br J Cancer, 106, 2012, 5.
31. Pil, L, Fobelets, M, Putman, K, Trybou, J, Annemans, L, Cost-effectiveness and budget impact analysis of a population-based screening program for colorectal cancer. Eur J Intern Med 32 (2016), 72–78.
32. Lansdorp-Vogelaar, I, Knudsen, AB, Brenner, H, Cost-effectiveness of colorectal cancer screening. Epidemiol Rev 33 (2011), 88–100.
33. Chen, LS, Liao, CS, Chang, SH, Lai, HC, Chen, TH, Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). J Med Screen 14 (2007), 191–199.
34. Zauber, AG, Knudsen, AB, Rutter, CM, Landsdorp-Vogelaar, I, Savarino, JE, van Ballegooijen, M, Kuntz, KM, Cost-Effectiveness of CT Colonography to Screen for Colorectal Cancer: Report to the Agency for Healthcare Research and Quality from the Cancer Intervention and Surveillance Modeling Network (CISNET) for MISCAN, SimCRC, and CRC-SPIN Models. https://www.cms.gov/Medicare/Coverage/DeterminationProcess/Downloads/id58TA.pdf, 2009 (accessed April 10, 2017).
35. Bolin, TD, Korman, MG, Nicholson, F, et al. Cost-effectiveness of screening for bowel cancer. Med J Aust 204 (2016), 11–12.
36. O'Leary, BA, Olynyk, JK, Neville, AM, Platell, CF, Cost-effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy. J Gastroenterol Hepatol 19 (2004), 38–47.
37. Graves, N, McKinnon, L, Leggett, B, Newman, B, Re-interpreting the data on the cost and effectiveness of population screening for colorectal cancer in Australia. Aust New Zealand Health Policy 2 (2005), 1–10.